FDA Grants Fast Track Designation to Jardiance for Kidney Disease

The FDA granted fast track designation to Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin) for reducing the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease.

The drug previously received a fast track designation in July 2019 for reducing the risk of cardiovascular death and hospitalization for heart failure in individuals with chronic heart failure.

Jardiance was first approved in ‎August 2014 as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes.